Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Tanaka, Sachiko ^a   Ishii, Atsuko ^a   Ohtaki, Hirokazu ^a   Shioda, Seiji ^a   Yoshida, Takemi ^a   Numazawa, Satoshi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

IL 1 ; Knockout mouse; Microglia; Neuroinflammation; Parkinson's disease

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ALPHA SYNUCLEIN; CD11B ANTIGEN; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC NERVE CELL; GENE; GENE REPRESSION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; LATENT PERIOD; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NERVE CELL STIMULATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN FUNCTION; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA; SYMPTOM; TH GENE; WILD TYPE;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALITIS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICROGLIA; PARKINSON DISEASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84888380685     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-143     Document Type: Article

References (43)

1. Quan N, Sundar SK, Weiss JM. Induction of interleukin-1 in various brain regions after peripheral and central injections of lipopolysaccharide. J Neuroimmunol 1994, 49:125-134. 10.1016/0165-5728(94)90188-0, 8294551.
2. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide. Brain Res Dev 2002, 133:27-35.
3. Gasparini L, Ongini E, Maucci R, Rosi S, Ronchetti D, Wenk G, McGann K, Hauss-Wegrzyniak B. Attenuation of chronic neuroinflammation by a nitric oxide releasing derivative of the antioxidant ferulic acid. J Neurochem 2004, 89:484-493. 10.1111/j.1471-4159.2004.02359.x, 15056291.
4. Fogal B, Hewett JA, Hewett SJ. Interleukin-1β potentiates neuronal injury in a variety of injury models involving energy deprivation. J Neuroimmunol 2005, 161:93-100. 10.1016/j.jneuroim.2004.12.007, 15748948.
5. Tanaka S, Ide M, Shibutani T, Ohtaki H, Numazawa S, Shioda S, Yoshida T. Lipopolysaccharide-induced microglial activation induces learning and memory deficits without neuronal cell death in rats. J Neurosci Res 2006, 83:557-566. 10.1002/jnr.20752, 16429444.
6. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291. 10.1212/WNL.38.8.1285, 3399080.
7. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993, 7:75-83. 10.1002/glia.440070113, 8423065.
8. Bo L, Monk S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994, 51:135-146. 10.1016/0165-5728(94)90075-2, 8182113.
9. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005, 58:963-967. 10.1002/ana.20682, 16240369.
10. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007, 69:1836-1842. 10.1212/01.wnl.0000279519.99344.ad, 17984451.
11. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev 2011, 11:CD008454.
12. Lindvall O, Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003, 100:13632-13637. 10.1073/pnas.2234031100, 263865, 14581618.
13. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144. 10.1146/annurev.neuro.22.1.123, 10202534.
14. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453. 10.1126/science.6610213, 6610213.
15. Dauter W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909. 10.1016/S0896-6273(03)00568-3, 12971891.
16. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Sudhof TC. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein. Proc Natl Acad Sci USA 2005, 102:3413-3418. 10.1073/pnas.0409713102, 552938, 15716361.
17. Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, Jenner P. 6-hydroxydopamine lesioning differentially affects α-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats. Neurosci Lett 2002, 322:33-36. 10.1016/S0304-3940(02)00083-6, 11958837.
18. Tanaka S, Kondo H, Kanda K, Ashino T, Nakamachi T, Sekikawa K, Iwakura Y, Shioda S, Numazawa S, Yoshida T. Involvement of interleukin-1 in lipopolysaccaride-induced microglial activation and learning and memory deficits. J Neurosci Res 2011, 89:506-514. 10.1002/jnr.22582, 21290410.
19. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, Takahashi M, Iwakura Y. Production of mice deficient in genes for interleukin (IL)-1α, IL-1β, IL1 α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998, 187:1463-1475. 10.1084/jem.187.9.1463, 2212263, 9565638.
20. Tagawa Y, Sekikawa K, Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol 1997, 159:1418-1428.
21. Ohtaki H, Funahashi H, Dohi K, Oguro T, Horai R, Asano M, Owakura Y, Yin L, Matsunaga M, Goto N, Shioda S. Suppression of oxidative neuronal damage after transient middle cerebral artery occlusion in mice lacking interleukin-1. Neurosci Res 2003, 45:313-324. 10.1016/S0168-0102(02)00238-9, 12631467.
22. Schmued LC, Albertson C, Slikker W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 1997, 751:37-46. 10.1016/S0006-8993(96)01387-X, 9098566.
23. Glowinski J, Iversen LL. Regional studies of catechol-amines in the rat brain. I. The disposition of [3H[norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 1966, 13:655-669. 10.1111/j.1471-4159.1966.tb09873.x, 5950056.
24. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLos One 2012, 7:e47387. 10.1371/journal.pone.0047387, 3474801, 23082161.
25. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994, 172:151-154. 10.1016/0304-3940(94)90684-X, 8084523.
26. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neurosci Lett 1994, 180:147-150. 10.1016/0304-3940(94)90508-8, 7700568.
27. Poot Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894. 10.1093/brain/awn101, 2442423, 18504291.
28. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflamm 2008, 5:8.
29. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005, 19:533-542. 10.1096/fj.04-2751com, 15791003.
30. Li P, Kaur C, Lu J, Sivakumar V, Dheen ST, Ling EA. Expression of cyclooxygenase-2 and microsomal prostaglandin-E synthase in amoeboid microglial cells in the developing brain and effects of cyclooxygenase-2 neutralization on BV-2 microglial cells. J Neurosci Res 2010, 88:1577-1594.
31. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53:S26-S38. 10.1002/ana.10483, 12666096.
32. Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends in Pharmacol Sci 2012, 33:295-303.
33. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47:S161-S170. 10.1212/WNL.47.6_Suppl_3.161S, 8959985.
34. Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J Neurosci Res 2005, 82:126-137. 10.1002/jnr.20595, 16108071.
35. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of Parkinsonian brains. J Neurochem 1991, 56:978-982. 10.1111/j.1471-4159.1991.tb02017.x, 1704426.
36. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 1997, 18:457-461. 10.1016/S0197-4580(97)00108-5, 9390770.
37. Fujita K, Seike T, Yutsudo N, Ohno M, Yamada H, Yamaguchi H, Sakumi K, Yamakawa Y, Kido MA, Takaki A, Katafuchi T, Tanaka Y, Nakabeppu Y, Noda M. Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1236-tetrahydropyridine mouse model of Parkinson's disease. PLoS One 2009, 4:e7247. 10.1371/journal.pone.0007247, 2747267, 19789628.
38. Liu W, Kato M, Akhand AA, Hayakawa A, Suzuki H, Miyata T, Kurokawa K, Hotta Y, Ishikawa N, Nakashima I. 4-hydroxynonenal induces a cellular redox, status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 2000, 113:635-641.
39. Ding M, St Pierre BA, Parkinson JF, Medberry P, Wong JL, Rogers NE, Ignarro LJ, Merrill JE. Inducible nitric-oxide synthase and nitric oxide production in human fetal astrocytes and microglia. J Biol Chem 1997, 272:11327-11335. 10.1074/jbc.272.17.11327, 9111039.
40. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992, 84:100-104. 10.1007/BF00427222, 1502878.
41. Choi DY, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, Shin EJ, Kim HC, Gash DM, Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. PLos One 2009, 4:e5482. 10.1371/journal.pone.0005482, 2674956, 19424495.
42. Mizushima H, Zhou CJ, Dohi K, Horai R, Asano M, Iwakura Y, Hirabayashi T, Arata S, Nakajo S, Takaki A, Ohtaki H, Shioda S. Reduced postischemic apoptosis in the hippocampus of mice deficient in interleukin-1. J Comp Neurol 2002, 448:203-216. 10.1002/cne.10262, 12012430.
43. Sato A, Ohtaki H, Tsumuraya T, Song D, Ohara K, Asano M, Iwakura Y, Atsumi T, Shioda S. Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury. J Neuroinflamm 2012, 9:65.